Stage IV Melanoma

Oncology
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
3
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
volociximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00369395Terminated19Est. Mar 2008
A
AngimmuneMD - Rockville
1 program
1
A-dmDT390-bisFvPhase 1/21 trial
Active Trials
NCT02990416UnknownEst. Jun 2018
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
1
KW-2871Phase 1/21 trial
Active Trials
NCT00199342Terminated5
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT01133977Completed97Est. Nov 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Abbottvolociximab
AngimmuneA-dmDT390-bisFv
EisaiLenvatinib
Kyowa Hakko KirinKW-2871

Clinical Trials (4)

Total enrollment: 121 patients across 4 trials

A Study of Volociximab in Metastatic Melanoma

Start: Dec 2006Est. completion: Mar 200819 patients
Phase 2Terminated
NCT02990416AngimmuneA-dmDT390-bisFv

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Start: Jan 2017Est. completion: Jun 2018
Phase 1/2Unknown

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Start: Apr 2010Est. completion: Nov 201497 patients
Phase 1/2Completed

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

Start: Nov 20045 patients
Phase 1/2Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space